Sort   by:  
 Page size 
UnknownVariability of oxygen requirements in critically ill COVID-19 patients.

Background

The global scarcity of medical oxygen has proven to be catastrophic during the surges in COVID-19 cases over the past two years, with the heaviest burden felt in low- and middle-income countries. Despite its criticality, data and analyses of oxygen consumption, even for typical cl...
S-EPMC10884784 | biostudies-literature
UnknownTocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Background

In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation.

Methods

This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOV...
S-EPMC8084355 | biostudies-literature
UnknownEarly short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis.

Background

The role of neuromuscular blocking agents (NMBAs) in coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS) is not fully elucidated. Therefore, we aimed to investigate in COVID-19 patients with moderate-to-severe ARDS the impact of early use of NMBAs on 90-...
S-EPMC9112652 | biostudies-literature
UnknownA prognostic signature for lung adenocarcinoma in patients who have never smoked.
Understanding tumor cell dynamics can improve prognosis and treatment but remains limited for lung adenocarcinoma in people who have never smoked (NS-LUAD). With RNA-seq data from 684 NS-LUAD and validation in an independent dataset, we identified three subtypes with distinct phenotypic traits and c...
S-EPMC12822368 | biostudies-literature
UnknownRevealing the Drivers Underlying Distinct Evolutionary Trajectories in Lung Adenocarcinoma.
Elucidating the evolution of cancers allows us to understand their key events, and the order in which they occur. To chart and interpret these evolutionary trajectories, we leverage whole-genome sequencing of lung tumours, including those from the largest cohort to date of lung cancers in subjects w...
S-EPMC12776081 | biostudies-literature
UnknownA prognostic signature for lung adenocarcinoma in people who have never smoked.
Knowledge of tumor cell dynamics can inform prognosis and treatment yet is largely lacking for lung adenocarcinoma in people who have never smoked (NS-LUAD). With RNA-seq data from 684 NS-LUAD and validation in an independent dataset, we identified three subtypes with distinct phenotypic traits and ...
S-EPMC12443039 | biostudies-literature
UnknownPanorama of Chromosomal Instability in Lung Cancer.
Lung cancer is a highly heterogeneous disease primarily driven by tobacco smoking. About 20% of lung cancers occur among patients who have never smoked (LCINS) with differences in patient ancestry, sex, tumor histology, and clinical features. Our understanding of chromosomal instability in lung canc...
S-EPMC12466783 | biostudies-literature
UnknownUncovering the role of LINE-1 in the evolution of lung adenocarcinoma.
Understanding lung cancer evolution can identify tools for intercepting its growth1,2. Here, in a landscape analysis of 1,024 lung adenocarcinomas (LUADs) with deep whole-genome sequencing integrated with multiomic data, we identified 542 LUADs with a diverse clonal architecture. In this ...
S-EPMC12823094 | biostudies-literature
UnknownDeciphering lung adenocarcinoma evolution and the role of LINE-1 retrotransposition.
Understanding lung cancer evolution can identify tools for intercepting its growth. In a landscape analysis of 1024 lung adenocarcinomas (LUAD) with deep whole-genome sequencing integrated with multiomic data, we identified 542 LUAD that displayed diverse clonal architecture. In this group, we obser...
S-EPMC11952568 | biostudies-literature
UnknownLong-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Background

For women with oestrogen receptor (ER)-positive early breast cancer, treatment with tamoxifen for 5 years substantially reduces the breast cancer mortality rate throughout the first 15 years after diagnosis. We aimed to assess the further effects of continuing tamoxifen to 10 year...
S-EPMC3596060 | biostudies-literature
Sort   by:  
 Page size